Important! Must Read! Demand Rising for 'Bootlegged' Weight-Loss Drug — As Novo Nordisk's Wegovy faces shortages, compounders step in to fill the gap, alarming doctors by Sophie Putka, Enterprise & Investigative Writer, MedPage Today July 7, 2022 Last Updated July 8, 2022

Novo Nordisk's weight management drug semaglutide (Wegovy) has been in prolonged short supply due to "unprecedented demand," prompting increased -- and questionable -- interest in compounded formulations of the drug, physicians said. 

Demand Rising for 'Bootlegged' Weight-Loss Drug | MedPage Today